RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus
PR Newswire Europe - Wed Jul 23, 9:12AM CDT
CALGARY, Alberta, July 23, 2014 /PRNewswire/ --
Resverlogix Secures an Additional $30 million from Citibank Loan
CNW Group - Thu Jul 03, 6:21PM CDT
Special Meeting of Shareholders Called to Approve
Leading Life Science Publication SciBX Highlights RVX-208
CNW Group - Wed May 21, 7:00AM CDT
"Most Advanced Epigenetic Drug in Clinical Development"
Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014
PR Newswire - Mon Mar 31, 12:00PM CDT
"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation"
Resverlogix Update
CNW Group - Mon Mar 17, 1:16PM CDT
"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets"
Resverlogix Board Update
CNW Group - Tue Feb 11, 4:00PM CST
TSX Exchange Symbol: RVX
Resverlogix Conference Call & Webcast Announcement
CNW Group - Thu Feb 06, 3:30PM CST
TSX Exchange Symbol: RVX
Resverlogix Announces Combined RVX-208 Findings from SUSTAIN & ASSURE Phase 2b Trials
PR Newswire Europe - Thu Jan 16, 4:54AM CST
CALGARY, Alberta, January 15, 2014 /PRNewswire/ --
Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
CNW Group - Thu Jan 02, 1:53PM CST
TSX Exchange Symbol: RVX